Myriad Genetics
MYGN
187 hedge funds and large institutions have $1.49B invested in Myriad Genetics in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 59 increasing their positions, 66 reducing their positions, and 27 closing their positions.
58% more capital invested
Capital invested by funds: $943M → $1.49B (+$545M)
49% more call options, than puts
Call options by funds: $4.39M | Put options by funds: $2.95M
1.62% more ownership
Funds ownership: 98.31% → 99.93% (+1.6%)
3% less funds holding
Funds holding: 192 → 187 (-5)
11% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 66
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EARNEST Partners
Atlanta,
Georgia
|
+$28.8M |
| 2 |
Morgan Stanley
New York
|
+$23.1M |
| 3 |
GCM
Glenview Capital Management
New York
|
+$14.9M |
| 4 |
Goldman Sachs
New York
|
+$8.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$8.33M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
CIBC Asset Management
Toronto,
Ontario, Canada
| – | -$133K | -10,190 | Closed |
|
|
PCM
202
Prelude Capital Management
New York
| – | -$66K | -5,029 | Closed |
|
|
QT
203
Quantbot Technologies
New York
| – | -$28K | -2,180 | Closed |
|
|
GT
204
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$27K | -2,099 | Closed |
|
205
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$15K | -1,163 | Closed |
|
206
Walleye Trading
New York
| – | -$11.9K | -737 | Closed |
|
|
CM
207
Castleark Management
Chicago,
Illinois
| – | -$3K | -240 | Closed |
|
|
CAL
208
Capital Analysts LLC
Fort Washington,
Pennsylvania
| – | -$3K | -200 | Closed |
|
|
PFS
209
Prospera Financial Services
Dallas,
Texas
| – | -$3K | -200 | Closed |
|
|
FGAM
210
Financial Gravity Asset Management
Lakeway,
Texas
| – | +$16 | +1 | New |
|
|
JFA
211
JNBA Financial Advisors
Bloomington,
Minnesota
| – | +$16 | +1 | New |
|
MYGN Hedge Fund Activity: Q4 2020 in Review
187 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q4 2020, worth a combined $1.49B — up 58% from $943M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MYGN and 23 opened new positions — a net loss of 4 holders — while 66 trimmed existing stakes and 59 added.
The largest buyer was EARNEST Partners, adding an estimated $28.8M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $11.5M.
- 187 institutional investors held Myriad Genetics (MYGN) as of Q4 2020, down from 192 in Q3 2020.
- Funds reported $1.49B of Myriad Genetics stock for Q4 2020, up 58% quarter-over-quarter.
- 23 funds opened new Myriad Genetics positions in Q4 2020 and 27 closed out, a net change of -4 holders.
- The largest Myriad Genetics buyer in Q4 2020 was EARNEST Partners, an estimated $28.8M added.
- The largest Myriad Genetics seller in Q4 2020 was Jacobs Levy Equity Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2020.